Innophos Holdings, Inc. Form 10-Q July 29, 2015 Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

-

FORM 10-Q

\_\_\_\_\_

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

For the quarterly period ended June 30, 2015

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

OF 1934

For the transition period from to

Commission File Number 001-33124

\_\_\_\_\_

INNOPHOS HOLDINGS, INC.

(Exact Name of Registrant as Specified in its Charter)

\_\_\_\_\_

Delaware 20-1380758
(State or Other Jurisdiction of Incorporation or Organization) Identification No.)

259 Prospect Plains Road

Cranbury, New Jersey 08512

(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: (609) 495-2495

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of "accelerated filer," "large accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer x Accelerated Filer o Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the

Exchange Act). Yes o No x

As of July 23, 2015, the registrant had 19,653,465 shares of common stock outstanding.

Page 1 of 36

### Table of Contents

### TABLE OF CONTENTS

PART I		Page
Item 1. Item 2. Item 3. Item 4.	Financial Statements Management's Discussion and Analysis of Financial Condition and Results of Operations Quantitative and Qualitative Disclosures About Market Risk Controls and Procedures	3 21 32 33
PART II		
Item 1. Item 1A. Item 2. Item 3. Item 4. Item 5. Item 6.	Legal Proceedings Risk Factors Unregistered Sales of Equity Securities and Use of Proceeds Defaults Upon Senior Securities Mine Safety Disclosures Other Information Exhibits	34 34 34 34 34 34 34 34
<u>Signatures</u>		<u>35</u>

Page 2 of 36

### PART I

### ITEM 1. FINANCIAL STATEMENTS

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited)

(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)

	June 30, 2015	December 31, 2014
ASSETS		
Current assets:		
Cash and cash equivalents	\$79,994	\$36,207
Accounts receivable, net	101,427	90,551
Inventories	175,044	184,621
Other current assets	46,348	60,135
Total current assets	402,813	371,514
Property, plant and equipment, net	197,037	198,988
Goodwill	84,373	84,373
Intangibles and other assets, net	68,387	73,536
Total assets	\$752,610	\$728,411
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Current portion of long-term debt	\$4,003	\$4,003
Accounts payable, trade and other	48,922	53,137
Other current liabilities	34,112	34,806
Total current liabilities	87,037	91,946
Long-term debt	240,000	132,002
Other long-term liabilities	40,858	41,456
Total liabilities	\$367,895	\$265,404
Commitments and contingencies (note 12)		
Common stock, par value \$.001 per share; authorized 100,000,000; issued 22,530,96	920	21
and 22,447,058; outstanding 20,001,272 and 21,480,334 shares	77 012	104 550
Paid-in capital	77,813	124,558
Common stock held in treasury, at cost (2,529,697 and 966,724 shares)	• • •	) (49,284 )
Retained earnings	396,032	390,525
Accumulated other comprehensive loss	` '	) (2,813 )
Total stockholders' equity	384,715	463,007
Total liabilities and stockholders' equity	\$752,610	\$728,411

See notes to condensed consolidated financial statements

Page 3 of 36

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Income (Unaudited)

(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)

	Three months June 30, 2015	s ended June 30, 2014	Six months e June 30, 2015	nded June 30, 2014	
Net sales	\$217,294	\$219,542	\$418,903	\$435,883	
Cost of goods sold	176,299	166,969	337,382	341,378	
Gross profit	40,995	52,573	81,521	94,505	
Operating expenses:					
Selling, general and administrative	18,667	19,683	36,658	38,656	
Research & development expenses	1,063	1,081	2,237	2,096	
Total operating expenses	19,730	20,764	38,895	40,752	
Operating income	21,265	31,809	42,626	53,753	
Interest expense, net	1,403	1,128	2,554	1,833	
Foreign exchange loss (gain)	117	(1,042)	2,432	(41	)
Income before income taxes	19,745	31,723	37,640	51,961	
Provision for income taxes	6,142	11,095	12,094	17,148	
Net income	\$13,603	\$20,628	\$25,546	\$34,813	
Net income attributable to participating common shareholder	rs\$13,571	\$20,585	\$25,500	\$34,740	
Per share data (note 2):					
Income per participating share:					
Basic	\$0.66	\$0.94	\$1.23	\$1.59	
Diluted	\$0.65	\$0.93	\$1.21	\$1.56	
Weighted average participating shares outstanding:					
Basic	20,435,846	21,876,265	20,807,777	21,870,343	,
Diluted	20,722,940	22,251,416	21,109,803	22,243,764	۲
Other comprehensive (loss) income, net of tax:					
Change in interest rate swaps, (net of tax (\$22), (\$236), \$245 and (\$268))		\$(384)	\$(401)	\$(436	)
Change in pension and post-retirement plans, (net of tax (\$7) (\$19), (\$108), and \$20)	<sup>'</sup> 14	(50)	312	72	
Other comprehensive (loss) income, net of tax Comprehensive income	\$50 \$13,653	\$(434 ) \$20,194	\$(89 ) \$25,457	\$(364 \$34,449	)

See notes to condensed consolidated financial statements

Page 4 of 36

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited) (Dollars in thousands)

	Six months ended		
	June 30,	June 30,	
	2015	2014	
Cash flows from operating activities			
Net income	\$25,546	\$34,813	
Adjustments to reconcile net income to net cash provided from operating activities:			
Depreciation and amortization	20,633	17,399	
Amortization of deferred financing charges	285	263	
Deferred income tax provision (benefit)	135	(71	)
Share-based compensation	1,585	1,975	
Changes in assets and liabilities:			
Increase in accounts receivable	(10,876	) (19,307	)
Decrease in inventories	9,573	17,200	
Decrease in other current assets	13,969	12,154	
Decrease in accounts payable	(4,144	) (920	)
(Decrease) increase in other current liabilities	(1,589	) 2,543	
Changes in other long-term assets and liabilities	135	1,978	
Net cash provided from operating activities	55,252	68,027	
Cash flows used for investing activities:			
Capital expenditures	(14,146	) (14,722	)
Net cash used for investing activities	(14,146	) (14,722	)
Cash flows used for financing activities:			
Proceeds from exercise of options	190	159	
Long-term debt borrowings	110,000		
Long-term debt repayments	(2,002	) (24,001	)
Excess tax benefits from exercise of stock options	764	154	
Common stock repurchases and restricted stock forfeitures	(86,248	) (6,381	)
Dividends paid	(20,061	) (17,546	)
Net cash provided from (used for) financing activities	2,643	(47,615	)
Effect of foreign exchange rate changes on cash and cash equivalents	38	23	
Net change in cash	43,787	5,713	
Cash and cash equivalents at beginning of period	36,207	32,755	
Cash and cash equivalents at end of period	\$79,994	\$38,468	

See notes to condensed consolidated financial statements

Page 5 of 36

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Statement of Stockholders' Equity (Unaudited)

(Dollars and shares in thousands)

(Donars and shares in thousands)										
	Number of Common Shares	Common Stock		Retained Earnings	Paid-in Capital		Accumulated Other Comprehens Income/(Los	ive	Total Shareholders' Equity	
Balance, December 31, 2013 Net income	21,893	\$22		\$364,515 64,461	\$100,447		\$ (1,565)	)	\$463,419 64,461	
Other comprehensive income, (net of tax \$598)							(1,248	)	(1,248	)
Proceeds from stock award exercises and issuances	119				160				160	
Share-based compensation					3,280				3,280	
Excess tax benefits from exercise of stock options					1,071				1,071	
Common stock repurchases Restricted stock forfeitures Dividends declared	(528 ) (4 )	(1	)	(38,451)	(29,482 (202	)			(29,483 (202 (38,451	)
Balance, December 31, 2014 Net income	21,480	\$21		\$390,525 25,546	\$75,274		\$ (2,813	)	\$463,007 25,546	,
Other comprehensive loss, (net of tax \$137)	f						(89	)	(89	)
Proceeds from stock award exercises and issuances	84				190				190	
Share-based compensation	(1.556	(1	`		1,585	,			1,585	`
Common stock repurchases  Excess tax benefits from exercise		(1	)		(85,847	)			(85,848	)
of stock options					764				764	
Restricted stock forfeitures Dividends declared	(7)			(20,039 )	(401	)			(401 (20,039	)
Balance, June 30, 2015	20,001	\$20		\$396,032	\$(8,435	)	\$ (2,902	)	\$384,715	

See notes to condensed consolidated financial statements

Page 6 of 36

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited) (Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)

### 1. Basis of Statement Presentation

Summary of Significant Accounting Policies

The accompanying unaudited condensed consolidated financial statements of Innophos Holdings, Inc. and Subsidiaries, or Company, have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S.) for interim financial reporting and do not include all disclosures required by generally accepted accounting principles in the U.S. for annual financial reporting, and should be read in conjunction with the audited consolidated and combined financial statements of the Company at December 31, 2014 and for the three years then ended.

The accompanying unaudited condensed consolidated financial statements of the Company reflect all adjustments which management considers necessary for a fair statement of the results of operations for the interim periods and is subject to year-end adjustments. The results of operations for the interim periods are not necessarily indicative of the results for the full year. The December 31, 2014 condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S. Certain prior year balances have been reclassified to conform to current year presentation.

Recently Issued Accounting Standards

Adopted

None.

Issued but not yet adopted

In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2017 (early adoption is permitted to the interim periods within the year of adoption). The guidance permits the use of either a retrospective or cumulative effect transition method. We have not yet selected a transition method and are currently evaluating the impact of the amended guidance on our consolidated financial position, results of operations and related disclosures.

In June 2014, the FASB issued guidance which requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The guidance is effective for the interim and annual periods beginning on or after December 15, 2015; early adoption is permitted. We do not anticipate that the adoption of this standard will have a material impact on our financial position, results of operations and related disclosures.

In August 2014 the FASB issued guidance which establishes management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern or to provide related footnote disclosures. The amendments require management to assess an entity's ability to continue as a going concern by incorporating and expanding upon certain principles in U.S. auditing standards. Specifically, ASU 2014-15 provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued or available to be issued. It also requires certain disclosures when substantial doubt is alleviated as a result

of consideration of management's plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The guidance is effective for the interim and annual periods beginning on or after December 15, 2016; early adoption is permitted. We do not anticipate that the adoption of this standard will have a material impact on our financial position, results of operations and related disclosures.

Page 7 of 36

### **Table of Contents**

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

In January 2015, the FASB issued new accounting rules which remove the concept of extraordinary items from U.S. GAAP. Under the existing guidance, an entity is required to separately disclose extraordinary items, net of tax, in the income statement after income from continuing operations if an event or transaction is of an unusual nature and occurs infrequently. This separate, net-of-tax presentation (and corresponding earnings per share impact) will no longer be allowed. The new rules will be effective for us in the first quarter of 2016. We do not anticipate the adoption of the new accounting rules will have a material impact on the our financial position, results of operations and related disclosures.

In February 2015, the Financial Accounting Standard Board issued amendments to the criteria for determining which entities are considered variable interest entities ("VIEs") and to the criteria for determining if a service provider possesses a variable interest in a VIE and ends the deferral granted to investment companies for application of the VIE consolidation model. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2015 and early adoption is permitted. We do not anticipate the adoption of the new accounting rules will have a material impact on the our financial position, results of operations and related disclosures. In April 2015, the Financial Accounting Standard Board issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2015, and early adoption is permitted. We do not anticipate the adoption of the new accounting rules will have a material impact on the our financial position, results of operations and related disclosures, although it will change the financial statement classification of our debt issuance costs. As of June 30, 2015, we have \$1.4 million of net deferred financing costs that would be reclassified from a long-term asset to a reduction in the carrying amount of our debt.

### 2. Earnings per share (EPS)

The Company accounts for earnings per share in accordance with ASC 260, which requires two calculations of earnings per share (EPS) to be disclosed: basic EPS and diluted EPS. Under ASC Subtopic 260-10-45, as of January 1, 2009 unvested awards of share-based payments with rights to receive dividends or dividend equivalents, such as our restricted stock, are considered participating securities for purposes of calculating EPS. Under the two-class method, a portion of net income is allocated to these participating securities and therefore is excluded from the calculation of EPS allocated to common stock, as shown in the table below.

The numerator for basic and diluted earnings per share is net earnings attributable to shareholders reduced by dividends attributable to unvested shares. The denominator for basic earnings per share is the weighted average number of common stock outstanding during the period. The denominator for diluted earnings per share is weighted average shares outstanding adjusted for the effect of dilutive outstanding stock options, performance share awards and restricted stock awards.

Page 8 of 36

### **Table of Contents**

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

The following is a reconciliation of the weighted average basic number of common shares outstanding to the diluted number of common and common stock equivalent shares outstanding and the calculation of earnings per share using the two-class method:

	Three Months Ended		Six Months Ended		
	June 30, 2015	June 30, 2014	June 30, 2015	June 30, 2014	
Net income	\$13,603	\$20,628	\$25,546	\$34,813	
Less: earnings attributable to unvested shares	(32)	(43)	(46)	(73)	
Net income available to participating common	\$13,571	\$20,585	\$25,500	\$34,740	
shareholders	\$13,371	\$20,363	\$23,300	\$34,740	
Weighted average number of participating common and					
potential common shares outstanding:					
Basic number of participating common shares	20,435,846	21,876,265	20,807,777	21,870,343	
outstanding	20,433,040	21,670,203	20,007,777	21,070,545	
Dilutive effect of stock equivalents	287,094	375,151	302,026	373,421	
Diluted number of weighted average participating common shares outstanding	20,722,940	22,251,416	21,109,803	22,243,764	
Earnings per participating common share:					
Earnings per participating common share—Basic	\$0.66	\$0.94	\$1.23	\$1.59	
Earnings per participating common share—Diluted	\$0.65	\$0.93	\$1.21	\$1.56	
Total outstanding options, performance share awards and	d				
unvested restricted stock not included in the calculation	391,069	292 071	276 127	205 701	
of diluted earnings per share as the effect would be	391,009	383,971	376,137	385,701	
anti-dilutive					

### 3. Dividends

The following is the dividend activity for the three months ended June 30, 2015 and June 30, 2014:

	Three Months Ended June 30		Six Months Ended June 30	
	2015	2014	2015	2014
Dividends declared – per share	\$0.48	\$0.40	\$0.96	\$0.80
Dividends declared – aggregate	9,863	8,780	20,061	17,546
Dividends paid – per share	0.48	0.40	0.96	0.80
Dividends paid – aggregate	9,863	8,780	20,061	17,546

We are a holding company that does not conduct any business operations of our own. As a result, we are dependent upon cash dividends, distributions and other transfers from our subsidiaries, most directly Innophos, Inc., our primary operating subsidiary, and Innophos Investments Holdings, Inc., its parent, to make dividend payments on our Common Stock.

### **Table of Contents**

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

### 4. Stockholders' Equity / Stock-Based Compensation

#### Restricted Stock

On May 8, 2015 there were a total of 24,164 restricted shares granted to certain employees with a fair value of \$1.2 million. These awards are classified as equity awards and vest annually over three years. The related compensation expense is based on the date of grant share price of \$49.54. The compensation expense is amortized on a straight-line basis over the requisite vesting period and accelerated for those employees that are retirement eligible during the vesting period.

### **Stock Options**

On May 8, 2015 the Company granted 102,766 non-qualified stock options at an exercise price of \$49.54 per share to certain employees with a fair value of \$1.7 million. The non-qualified stock options vest annually over three years with a May 8, 2025 expiration date.

The fair value of the options granted during 2015 was determined using the Black-Scholes option-pricing model. The assumptions used in the Black-Scholes option-pricing model were as follows:

Non-qualified stock options
-----------------------------

Expected volatility	46.3	%
Dividend yield	3.3	%
Risk-free interest rate	1.7	%
Expected term (years)	6.3	
Weighted average grant date fair value of stock options	\$16.46	

For the 2015 grants the expected volatility and the expected term are based on the Company's historical data. The dividend yield is the expected annual dividend payments divided by the average stock price up to the date of grant. The risk-free interest rates are derived from the U.S. Treasury securities in effect on the date of grant whose maturity period equals the options expected term. The Company applies an expected forfeiture rate to stock-based compensation expense. The estimate of the forfeiture rate is based primarily upon historical experience of employee turnover. As actual forfeitures become known, stock-based compensation expense is adjusted accordingly. Performance Share Awards

On May 8, 2015, the Company granted 40,272 performance shares to certain employees with a fair value of \$2.0 million. The performance shares vest at the end of the three year performance cycle and the number of shares distributable depends on the extent to which the Company attains pre-established performance goals. Amounts equivalent to declared dividends will accrue on the performance shares and will vest over the same period. Stock Grants

In May 2015 the six external members of the Board of Directors were granted a combined total of 9,792 shares of the Company's common stock with an aggregated fair value of approximately \$0.5 million which immediately vested as part of their director fees.

The Board of Directors authorized a new stock repurchase program, commencing January 1, 2015, pursuant to which the Company intends to acquire for cash in open market or private transactions from time to time up to \$125 million of its common stock over the ensuing 12 months. The timing of repurchases and the exact number of shares of common stock to be purchased will depend upon market conditions and other factors. The repurchase program will be funded through existing liquidity, including possible borrowings from the Senior Credit Facility (see Note 9), and cash from operations. Treasury stock is recognized at the cost to reacquire the shares. Under the stock repurchase program, during the six months ended June 30, 2015, the Company repurchased 1,555,726 shares of its common stock on the open market at an average price of 55.18 per share or \$85.8 million.

### **Table of Contents**

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

The following table summarizes the components of stock-based compensation expense, all of which has been classified as selling, general and administrative expense:

	Three Mont	Three Months Ended		s Ended
	June 30,	June 30,	June 30,	June 30,
	2015	2014	2015	2014
Stock options	\$454	\$245	\$702	\$815
Restricted stock	392	261	638	557
Performance shares	46	41	(265	) 333
Stock grants	510	270	510	270
Total share-based compensation expense	\$1,402	\$817	\$1,585	\$1,975

### 5. Inventories

Inventories consist of the following:

	June 30,	December 31,
	2015	2014
Raw materials	\$52,480	\$60,697
Finished products	109,270	111,600
Spare parts	13,294	12,324
	\$175,044	\$184,621

Inventory reserves for excess quantities, obsolescence or shelf-life expiration as of June 30, 2015 and December 31, 2014 were \$12,736 and \$12,626, respectively.

### 6. Other Current Assets

Other current assets consist of the following:

	June 30,	December 31,
	2015	2014
Creditable taxes (value added taxes)	14,323	\$18,124
Vendor inventory deposits (prepaid)	9,607	9,483
Prepaid income taxes	6,581	12,658
Deferred income taxes	12,142	12,647
Prepaid insurance	739	2,109
Other	2,956	5,114
	\$46,348	\$60,135

Page 11 of 36

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

### 7. Intangibles and Other Assets, net

Intangibles and other assets consist of the following:

	Useful life (years)	June 30, 2015	December 31, 2014
Developed technology and application patents, net of accumulated amortization of \$23,371 for 2015 and \$21,894 for 2014	7-20	\$22,904	\$24,381
Customer relationships, net of accumulated amortization of \$14,433 for 2015 and \$13,054 for 2014	5-15	24,379	25,758
Trade names and license agreements, net of accumulated amortization of \$8,258 for 2015 and \$7,573 for 2014	5-20	9,403	10,088
Non-compete agreements, net of accumulated amortization of \$1,033 for 2015 and \$954 for 2014	<sup>3</sup> 3-10	300	379
Total intangibles		\$56,986	\$60,606
Deferred financing costs, net of accumulated amortization of \$2,463 for 2015 and \$2,178 for 2014 (see note 9)		\$1,388	\$1,673
Other tax assets		6,724	7,013
Other assets		3,289	4,244
Total other assets		\$11,401	\$12,930
		\$68,387	\$73,536

### 8. Other Current Liabilities

Other current liabilities consist of the following:

	June 30,	December 31,
	2015	2014
Payroll related	\$9,718	\$12,703
Taxes other than income taxes	5,238	5,057
Benefits and pensions	4,550	6,640
Freight and rebates	3,959	4,346
Income taxes	2,497	1,302
Equity repurchases	2,700	_
Other	5,450	4,758
	\$34,112	\$34,806

## 9. Short-term Borrowings, Long-Term Debt, and Interest Expense Short-term borrowings and long-term debt consist of the following:

	June 30,	December 31,
	2015	2014
Term loan due 2017	\$90,000	\$92,000
Revolver borrowings under the credit facility	154,000	44,000
Capital leases	3	5
Total borrowings	\$244,003	\$136,005

 Less current portion
 4,003
 4,003

 Long-term debt
 \$240,000
 \$132,002

Page 12 of 36

### **Table of Contents**

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

The Company's credit facility includes a term loan of \$100.0 million and a revolving line of credit from the Lenders of up to \$225.0 million, including a \$20.0 million letter of credit sub-facility, all maturing on December 21, 2017. Repayments of the term loan are required at the rate of 1% of original principal amount per quarter beginning on March 31, 2013.

As of June 30, 2015, \$90.0 million was outstanding under the Term Loan and \$154.0 million was outstanding under the revolving line of credit, both of which approximate fair value because they have a floating interest rate (determined using level 2 inputs within the fair value hierarchy) with total availability at \$70.1 million, taking into account \$0.9 million in face amount of letters of credit issued under the sub-facility. The current weighted average interest rate for all debt is 2.2%.

Among its affirmative covenants, the Credit Agreement requires the Companies to maintain the following consolidated

ratios (as defined and calculated according to the Credit Agreement) as of the end of each fiscal quarter:

- (a) "Total Leverage Ratio" less than or equal to 3.00 to 1.00.
- (b) "Senior Leverage Ratio" less than or equal to 2.50 to 1.00.
- (c) "Fixed Charge Coverage Ratio" greater than or equal to 1.25 to 1.00.

As of June 30, 2015, the Company was in full compliance with all debt covenant requirements.

As a result of lower than expected earnings for 2015 combined with the increased borrowings to fund the share repurchase program, the Company's Senior Leverage Ratio has increased from 0.98 as of December 31, 2014 to 1.89 as of June 30, 2015. In order to make restricted payments such as share repurchases or dividends, the Company must pass an incurrence test of (a) the Total Leverage Ratio and Senior Leverage Ratio shall be 0.50 less than the applicable covenant level and (b) accessible borrowing availability of at least \$25.0 million. The applicable Senior Leverage Ratio for the incurrence test is 2.00 to 1.00 which the Company is in compliance with at June 30, 2015. The Company is currently negotiating with the lenders to amend the Credit Agreement to adjust or remove the Senior Leverage Ratio. In the event of unsuccessful negotiations with the lenders, the Company may have to take other courses of action, including but not limited to decreasing the rate of share repurchases.

Simultaneous with the term of the credit facility, Innophos entered into an interest rate swap, swapping the LIBOR exposure on \$100.0 million adjusting quarterly consistent with the Term Loan, with a fixed rate of 0.9475% plus the applicable margin on the debt expiring in December 2017. This interest rate swap has been designated as a cashflow hedge (Level 2) with the changes in value recorded through other comprehensive income. The fair value of this interest rate swap is a liability of approximately \$0.1 million as of June 30, 2015.

We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with our credit status.

Total interest paid by the Company for all indebtedness for the six months ended June 30, 2015 and June 30, 2014 was \$2,326 and \$2,160, respectively.

Interest expense, net consists of the following:

	Three months ended		Six month:	s ended	
	June 30,	June 30,	June 30,	June 30,	
	2015	2014	2015	2014	
Interest expense	\$1,306	\$1,022	\$2,332	1,607	
Deferred financing cost	142	131	285	263	
Interest income	(30	) (9	) (37	) (14	)
Less: amount capitalized for capital projects	(15	) (16	) (26	) (23	)

Total interest expense, net \$1,403 \$1,128 \$2,554 \$1,833

Page 13 of 36

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

### 10. Other Long-Term Liabilities

Other long-term liabilities consist of the following:

	June 30,	December 31,
	2015	2014
Deferred income taxes	\$23,568	\$24,400
Pension and post retirement liabilities	10,526	10,714
Uncertain tax positions	2,744	2,798
Environmental liabilities	1,100	1,100
Other liabilities	2,920	2,444
	\$40.858	\$41.456

#### 11. Income Taxes

The effective income tax rate on income before taxes was approximately 32% for the six months ended June 30, 2015 compared to approximately 33% for the comparable period in 2014. The variance in the effective tax rate is primarily due to uncertain income tax position benefits which decreased the effective tax rate by 1% in the prior year and R&D and state

research and development credits which decreased the prior year effective tax rate by 1%, more than offset by increased taxable income in lower tax rate jurisdictions in the current year.

Business is conducted in various countries throughout the world and is subject to tax in numerous jurisdictions. A significant number of tax returns are filed and subject to examination by various federal, state and local tax authorities. Tax examinations are often complex, as tax authorities may disagree with the treatment of items reported requiring several years to resolve. As such, the Company maintains liabilities for possible assessments by tax authorities resulting from known tax exposures for uncertain income tax positions. The Company's policy is to accrue associated penalties in selling, general and administrative expenses and to accrue interest in net interest expense. Currently, the Company is under examination, or has been contacted for examination on income tax returns for the years 2007 through 2012. In addition, Innophos Canada, Inc. was assessed approximately \$3.5 million for the tax years 2007 and 2008 by the Canadian tax authorities. The Company is contesting the full assessment. After lengthy discussions, the Canadian tax authorities have reassessed these amounts in August 2014 and the Company filed a Notice of Objection with the Canada Revenue Agency Appeals Board in November 2014. The Company believes that its tax position is more likely than not to be sustained. It is reasonably possible that new issues will be raised by tax authorities which may require adjustments to the amount of unrecognized tax benefits as of June 30, 2015. Other than the items mentioned above, as of June 30, 2015, no material adjustments have been proposed to the Company's tax positions and the Company currently does not anticipate any adjustments that would result in a material change to its financial position during the next twelve months.

Income taxes (refunded)/paid were \$3,175 and \$18,010 for the six months ended June 30, 2015 and June 30, 2014, respectively.

### 12. Commitments and Contingencies

### Environmental

The Company's operations are subject to extensive and changing federal and state environmental laws and regulations. The Company's manufacturing sites have an extended history of industrial use, and soil and groundwater contamination have or may have occurred in the past and might occur or be discovered in the future.

Environmental efforts are difficult to assess for numerous reasons, including the discovery of new remedial sites, discovery of new information and scarcity of reliable information pertaining to certain sites, improvements in technology, changes in environmental laws and regulations, numerous possible remedial techniques and solutions, difficulty in assessing the involvement of and the financial capability of other potentially responsible parties and the extended time periods over which remediation occurs. Other than the items listed below, the Company is not aware of material environmental liabilities which are probable and estimable. As the Company's environmental contingencies are more clearly determined, it is reasonably possible that amounts may need to be accrued. However, management does not believe, based on current information, that

Page 14 of 36

### **Table of Contents**

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

environmental remediation requirements will have a material impact on the Company's results of operations, financial position or cash flows.

Future environmental spending is probable at our site in Nashville, TN, the eastern portion of which had been used historically as a landfill, and a western parcel previously acquired from a third party, which reportedly had housed, but no longer does, a fertilizer and pesticide manufacturing facility. We have an estimated liability with a range of \$0.9 million-\$1.3 million. The remedial action plan for that site has yet to be finalized, and as such, the Company has recorded a liability, which represents the Company's best estimate, of \$1.1 million as of June 30, 2015. Litigation

2008 RCRA Civil Enforcement - Geismar, Louisiana plant

Following several inspections by the Environmental Protection Agency, or EPA, at our Geismar, LA purified phosphoric acid, or PPA, plant and related submissions we made to support claimed exemptions from the federal Resource, Conservation and Recovery Act, or RCRA, in March 2008, EPA referred our case to the Department of Justice, or DOJ, for civil enforcement. Although no citations were ever issued or formal proceedings instituted, the agencies claim we violate RCRA by failing to manage appropriately two materials that DOJ/EPA alleges are hazardous wastes. Those materials are: (i) Filter Material from an enclosed intermediate filtration step to further process green phosphoric acid we receive as raw material via pipeline from the adjacent site operated by an affiliate of Potash Corporation of Saskatchewan, or PCS; and (ii) Raffinate, a co-product we return to PCS under a long-term contract we have with PCS.

Since referral of the case to DOJ, we and PCS have engaged in periodic discussions with DOJ/EPA and the Louisiana Department of Environmental Quality, or LDEQ, or collectively the Government Parties, in order to resolve the matter. In addition to asserting that the two materials in question are not hazardous wastes, we have also sought to demonstrate that both the nature and character of the materials as well as their use, handling and disposition were detailed in a solid waste permit amendment application filed in 1989 by PCS's predecessor, when our plant was first constructed, and approved by the LDEQ under the state RCRA program.

In the course of discussions with the Government Parties, the DOJ/EPA has required that we undertake, as an interim measure, the construction of a new filter unit to replace the closed system and allow the removal and separate handling of the Filter Material. We built that unit, which has been operating since 2012.

In an attempt to address the remaining concerns of the Government Parties, we and PCS undertook joint efforts to explore possible technical solutions to the issue of Raffinate treatment. Based upon work so far, there appears to be at least one technically viable approach, namely that of "deep well injection," which we believe is acceptable to regulators as part of a negotiated solution among the parties.

Although we cannot give assurances as to the future course or ultimate outcome of ongoing negotiations, including whether litigation may ultimately ensue, we believe, based on our appreciation of the current state of the proceedings, that deep well injection is likely to be employed as the technologically acceptable approach for Raffinate and that we will not be asked to contribute substantially to the cost of the deep well to be specified by the Government Parties in an anticipated consent decree for settlement of this enforcement matter. However, in negotiated settlements leading to consent decrees with the Governmental Parties, it is also common for penalties relating to previous "non-compliance" to be assessed and, in that connection, we have been advised by the Governmental Parties that they expect to seek penalties against both PCS and us in this case. Although we have argued and made submissions to the effect that for purposes of settlement penalties there is no basis for any substantial penalty to be levied against us, nevertheless, we can give no assurance as to that outcome, or if a penalty is initially assessed as to its amount, or whether it will be necessary for us to oppose or seek indemnity for the assessment by further litigation. Based upon our receipt of a draft consent decree from the Government Parties in June 2014 and subsequent discussions with them, we have established an accrual of \$0.9 million for settlement civil penalties. However, further discussions among all parties will be necessary to determine if the matter can be resolved by settlement.

Other Legal Matters

In March 2008, Sudamfos S.A., or Sudamfos, an Argentine phosphate producer, filed an arbitration before the ICC International Court of Arbitration, Paris, France, concerning an alleged agreement for our Mexicana subsidiary, Mexicana, to sell it 12,500 metric tons of phosphoric acid, but subsequently withdrew the proceeding. In October 2008, Mexicana filed suit in Mexico against Sudamfos to collect approximately \$1.2 million representing the contract price for prior deliveries of phosphoric acid for which Sudamfos had refused to pay. In October 2009, Sudamfos answered the suit and counterclaimed for

Page 15 of 36

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

\$3.0 million based upon the agreement originally alleged in the arbitration. In subsequent proceedings including available appeals, Mexicana's claim was sustained and Sudamfos' counterclaim was denied. Mexicana has now begun formal collection proceedings against Sudamfos.

In July 2013, Innophos, Inc. was assessed approximately \$1.2 million of sales/use taxes by the State of Louisiana and Ascension Parish. This tax assessment covers certain raw materials used in the production of Phosphoric Acid. The Company is contesting both tax assessments. This assessment covers periods 2004 to 2010 for the Parish and 2007 to 2010 for the State. We have concluded that the contingent liability arising from this matter is neither remote nor probable, but reasonably possible.

In addition, we are party to legal proceedings and contractual disputes that arise in the ordinary course of our business. Except as to the matters specifically discussed, management believes that these matters represent remote liabilities. However, these matters cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, results of operations, financial condition, and/or cash flows.

### 13. Pension Plans and Postretirement Benefits

Net periodic benefit expense for the United States plans:

	For the thre 2015	e months end	ed June 30,	For the three 2014	e months ende	ed June 30,	
	Pension benefits	Other benefits	Total	Pension benefits	Other benefits	Total	
Service cost	\$	\$79	\$79	<b>\$</b> —	\$78	\$78	
Interest cost	28	42	70	31	43	74	
Expected return on assets	(34)		(34)	(31)		(31	)
Amortization of							
prior service cost						_	
unrecognized (gain) loss	16	(5)	11		(10)	(10	)
Net periodic cost	\$10	\$116	\$126	<b>\$</b> —	\$111	\$111	
*							
	For the six	months ended	June 30,	For the six r	nonths ended	June 30,	
	For the six 1 2015	months ended	June 30,	For the six r 2014	nonths ended	June 30,	
		months ended Other benefits	June 30, Total		onths ended Other benefits	June 30, Total	
Service cost	2015 Pension	Other		2014 Pension	Other		
Service cost Interest cost	2015 Pension	Other benefits	Total	2014 Pension benefits	Other benefits	Total	
Interest cost Expected return on assets Amortization of	2015 Pension benefits —	Other benefits \$159	Total \$159	2014 Pension benefits \$—	Other benefits \$156	Total \$156	)
Interest cost Expected return on assets Amortization of prior service cost	2015 Pension benefits — 57 (69)	Other benefits \$159 84 —	Total \$159 141 (69 )	2014 Pension benefits \$— 61	Other benefits \$156 87	Total \$156 148 (61	)
Interest cost Expected return on assets Amortization of	2015 Pension benefits — 57	Other benefits \$159	Total \$159 141	2014 Pension benefits \$— 61	Other benefits \$156	Total \$156 148	)

In April 2015, Innophos contributed approximately \$0.1 million to its U.S. defined benefit pension plan to satisfy the full year 2015 minimum contribution requirements.

Innophos made its entire cash contribution of \$3.0 million for the U.S. defined contribution plan during the first quarter of 2015 for the plan year 2014.

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Net periodic benefit expense for the Canadian plans:

	For the th 2015	ree mon	ths ended June 30	),	For the the 2014	iree	e months end	led June 30	),
	Pension benefits	Othe bene	Total		Pension benefits		Other benefits	Total	
Service cost	\$89	\$12	\$101		\$80		\$17	\$97	
Interest cost	131	14	145		145		21	166	
Expected return on assets	(200	) —	(200	)	(234	)	_	(234	)
Amortization of									
actuarial loss (gain)	41		41		25		4	29	
prior service cost	29		29		23			23	
net transition obligation		6	6				7	7	
Exchange rate changes	(128	) 29	(99	)	(244	)	53	(191	)
Net periodic cost	\$(38	) \$61	\$23		\$(205	)	\$102	\$(103	)
			1 1 7 20					1.1 20	
	For the single 2015	x months	s ended June 30,		For the si 2014	Хľ	nonths ended	1 June 30,	
		x months Othe	r Total			хr	Other benefits	Total	
Service cost	2015 Pension	Othe	r Total		2014 Pension	x r	Other		
Service cost Interest cost	2015 Pension benefits	Othe bene	r Total		2014 Pension benefits	Хľ	Other benefits	Total	
	2015 Pension benefits \$178	Othe bene \$24	r Total \$202	)	2014 Pension benefits \$159 287	) )	Other benefits \$34	Total \$193	)
Interest cost	2015 Pension benefits \$178 262	Othe bene \$24	Total \$202 290	)	2014 Pension benefits \$159 287	) )	Other benefits \$34	Total \$193 330	)
Interest cost Expected return on assets	2015 Pension benefits \$178 262	Othe bene \$24	Total \$202 290	)	2014 Pension benefits \$159 287	)	Other benefits \$34	Total \$193 330	)
Interest cost Expected return on assets Amortization of	2015 Pension benefits \$178 262 (400	Othe bene \$24	Total \$202 290 (400	)	2014 Pension benefits \$159 287 (466	)	Other benefits \$34 43 —	Total \$193 330 (466	)
Interest cost Expected return on assets Amortization of actuarial loss (gain)	2015 Pension benefits \$178 262 (400	Othe bene \$24	Total \$202 290 (400	)	2014 Pension benefits \$159 287 (466	)	Other benefits \$34 43 —	Total \$193 330 (466	)
Interest cost Expected return on assets Amortization of actuarial loss (gain) prior service cost	2015 Pension benefits \$178 262 (400	Othe bene \$24 28 ) —	Total \$202 290 (400	)	2014 Pension benefits \$159 287 (466	)	Other benefits \$34 43 — 7 —	Total \$193 330 (466 57 47	)

Innophos Canada, Inc. does not plan to make cash contributions to its Canadian defined benefit plan in 2015.

Page 17 of 36

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

### 14. Accumulated Other Comprehensive Income (Loss)

Changes in Accumulated Other Comprehensive Income by Component:

Changes in Accumulated Other Comprehensive mediae by Component				
	Pension and	Changes in		
For the three months ended June 30, 2015	Other	Fair Value of	Total	
For the timee months ended June 30, 2013	Postretirement	Effective Cash	Total	
	Adjustments	Flow Hedges		
Balance at March 31, 2015	-	\$(75)	\$(2,952	)
Other comprehensive income (loss) before reclassifications	14	36	50	
Amounts reclassified from accumulated other comprehensive incom-		_	_	
Net current period other comprehensive income (loss)	14	36	50	
Balance at June 30, 2015		\$(39)	*	)
2444400 40040 00, 2010	ψ( <b>2</b> ,000)	Ψ(ε)	ψ ( <b>=</b> ,> 0 <b>=</b>	,
	Pension and	Changes in		
	Other	Fair Value of		
For the three months ended June 30, 2014	Postretirement	Effective Cash	Total	
	Adjustments	Flow Hedges		
Polongo et March 21, 2014	-	\$670	\$(1,495	`
Balance at March 31, 2014				)
Other comprehensive income before reclassifications	(50)	(384)	(434	)
Amounts reclassified from accumulated other comprehensive incom-		(204		,
Net current period other comprehensive income	(50 )	(384)	(434	)
Balance at June 30, 2014	\$(2,215)	\$286	\$(1,929	)
	ъ : 1	CI.		
	Pension and	Changes in		
For the six months ended June 30, 2015	Other	Fair Value of	Total	
	Postretirement	Effective Cash		
	Adjustments	Flow Hedges		
Balance at December 31, 2014		\$362	\$(2,813	)
Other comprehensive income (loss) before reclassifications	312	(401)	(89	)
Amounts reclassified from accumulated other comprehensive incom-	e			
(loss)				
Net current period other comprehensive income (loss)	312	(401)	(89	)
Balance at June 30, 2015	\$(2,863)	\$(39)	\$(2,902	)
	Pension and	Changes in		
For the six months and addings 20, 2014	Other	Fair Value of	T-4-1	
For the six months ended June 30, 2014	Postretirement	Effective Cash	Total	
	Adjustments	Flow Hedges		
Balance at December 31, 2013	\$(2,287)		\$(1,565	)
Other comprehensive income (loss) before reclassifications	72	(436)	(364	)
Amounts reclassified from accumulated other comprehensive incom-		, , ,	(	,
(loss)			<del></del>	
Net current period other comprehensive income (loss)	72	(436)	(364	)
Balance at June 30, 2014		\$286	\$(1,929	)
Datance at June 30, 2017	ψ(2,213 )	Ψ 200	Ψ(1,)Δ)	,

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

### 15. Segment Reporting

The company discloses certain financial and supplementary information about its reportable segments, revenue by products and revenues by geographic area. Operating segments are defined as components of an enterprise about which separate discrete financial information is evaluated regularly by the chief operating decision maker, in order to decide how to allocate resources and assess performance. The primary performance indicators for the chief operating decision maker are sales and operating income, with sales presented on a ship-from basis. All references to sales in this Form 10-Q, either on a ship-from or ship-to basis, are on the same basis of revenue recognition and are recognized when title and risk of loss passes to the customer, which occurs either upon shipment or delivery, depending upon the agreed sales terms with customers.

The Company's reportable segments reflect the core businesses in which Innophos operates and how it is managed. The Company reports its core specialty phosphates business separately from granular triple super-phosphate, or GTSP, and other non-specialty phosphate products (GTSP & Other). Innophos Nutrition (formerly Kelatron, AMT, Triarco and CMI) is included in the Specialty Phosphates US & Canada segment and in the Specialty Ingredients product line. Specialty Phosphates consists of the products lines Specialty Ingredients, Food & Technical Grade PPA, and STPP & Detergent Grade PPA. GTSP & Other includes fertilizer co-product GTSP and other non-specialty phosphate products.

For the three months ended June 30, 2015	Specialty Phosphates US & Canada	Specialty Phosphates Mexico	GTSP & Other	Eliminations	Total
Sales	\$148,376	\$43,886	\$25,032	<b>\$</b> —	\$217,294
Intersegment sales	2,535	14,495	86	(17,116 )	
Total sales	\$150,911	\$58,381	\$25,118	\$(17,116)	\$217,294
Operating income	\$13,470	\$7,362	\$433	\$	\$21,265
Depreciation and amortization expense	\$6,786	\$3,196	\$780	<b>\$</b> —	\$10,762
For the three months ended June 30, 2014	Specialty Phosphates US & Canada	Specialty Phosphates Mexico	GTSP & Other	Eliminations	Total
	Phosphates	Phosphates		Eliminations \$—	Total \$219,542
30, 2014	Phosphates US & Canada	Phosphates Mexico	Other		
30, 2014 Sales	Phosphates US & Canada \$157,267	Phosphates Mexico \$40,885	Other \$21,390	<b>\$</b> —	\$219,542
30, 2014 Sales Intersegment sales	Phosphates US & Canada \$157,267 796	Phosphates Mexico \$40,885 15,139	Other \$21,390 38	\$— (15,973 )	\$219,542 —

Page 19 of 36

### INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

For the six months ended June 30, 2015	Specialty Phosphates US & Canada	Specialty Phosphates Mexico	GTSP & Other	Eliminations	Total
Sales	\$295,500	\$86,106	\$37,297	<b>\$</b> —	\$418,903
Intersegment sales	5,961	28,217	145	(34,323	) —
Total sales	\$301,461	\$114,323	\$37,442	\$(34,323	\$418,903
Operating income	\$29,657	\$14,281	\$(1,312	\$	\$42,626
Depreciation and amortization expense	\$13,725	\$5,294	\$1,614		\$20,633
For the six months ended June 30, 2014	Specialty Phosphates US & Canada	Specialty Phosphates Mexico	GTSP & Other	Eliminations	Total
-	Phosphates	Phosphates		Eliminations	Total \$435,883
2014	Phosphates US & Canada	Phosphates Mexico	Other	Eliminations (29,346	
2014 Sales	Phosphates US & Canada \$308,277	Phosphates Mexico \$85,374	Other \$42,232		\$435,883
2014 Sales Intersegment sales	Phosphates US & Canada \$308,277 1,550	Phosphates Mexico \$85,374 27,757	Other \$42,232 39	(29,346	\$435,883 ) —

Page 20 of 36

# ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This discussion contains forward-looking statements about our markets, the demand for our products and services and our future results. We based these statements on assumptions that we consider reasonable. Actual results may differ materially from those suggested by our forward-looking statements for various reasons including those discussed in the "Risk Factors" and "Forward-Looking Statements" sections of this report.

Innophos is a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets. Innophos combines more than a century of experience in specialty phosphate manufacturing with a growing capability in a broad range of other specialty ingredients to supply a product range produced to stringent regulatory manufacturing standards and the quality demanded by customers worldwide. Many of Innophos' products are application-specific compounds engineered to meet customer performance requirements and are often critical to the taste, texture and performance of foods, beverages, pharmaceuticals, dietary supplements, oral care products and other applications. For example, Innophos products act as flavor enhancers in beverages, electrolytes in sports drinks, texture additives in cheeses, leavening agents in baked goods, pharmaceutical excipients, cleaning agents in toothpaste and provide a wide range of nutritional fortification solutions for food, beverage and nutritional supplement manufacturers.

Page 21 of 36

### Recent Trends and Outlook

Financial performance in the second quarter mirrored the first quarter 2015, with not much change regarding the overall business drivers and challenges. Specialty Phosphates volumes were down 1% for the second quarter 2015 compared to the prior year period. Soft firefighting and processed foods market demand, competitive pricing pressures and the strong US dollar effects seen since the fourth quarter 2014 continued through the second quarter 2015. Export sales were down 5% year-over-year for the second quarter due to order patterns for Europe, Middle East and Africa and lingering effects on sales to Asia from the dockworkers slowdown at US West Coast ports, which returned to normal operations during the quarter. The Specialty Phosphates volume outlook continues to be flat for full year 2015 compared to 2014, with second half 2015 year-over-year comparable expected to recover first half 2015 shortfalls due to low second half 2014 PPA volumes caused by supply issues during that period.

Specialty Phosphates operating income margins were 11% for the second quarter 2015, and the first half 2015 margin of 12% was at the low end of the expected full year range. Recently implemented selling price increases are expected to improve margins in the second half of the year from the second quarter 2015 levels, maintaining management's full year expectation for margins in the 12-13% range.

Given the 2015 margin compression that the Company is experiencing, management is currently evaluating several initiatives to improve the overall operating efficiency of the organization, targeting to at least cover the 100 basis points cost component of the margin compression. These initiatives may require various one-time costs such as capital spending, involuntary and/or voluntary separation costs. The various initiatives being reviewed include production unit consolidations and various staff reduction initiatives. The Company intends to conclude the evaluation of these initiatives and seek Board approval by the end of the third quarter 2015.

Reported fertilizer market prices showed a slightly declining trend during the second quarter of 2015 and are currently 5-10% below prior year levels. Demand improved sequentially due to seasonality but still remained weaker than normal. Market phosphate rock prices were stable sequentially in the second quarter 2015 and are expected to remain stable for the third quarter. Sulfur market prices decreased approximately 10% sequentially in the second quarter 2015 and are expected to remain stable for the third quarter.

GTSP & Other recorded break even operating income for the second quarter 2015, in line with expectations and the prior year quarter. The company expects an operating result close to break even for the third quarter as well. Net debt (total long-term debt (including any current portion) less cash and cash equivalents) increased sequentially by just \$16 million in the second quarter 2015 while \$62 million was returned to shareholders via dividends and stock buybacks. The strong cash flow was aided by a \$29 million decrease in working capital which more than reversed the \$21 million working capital increase in the first quarter 2015.

Page 22 of 36

### Historical Performance

Results of Operations

The following table sets forth a summary of the Company's operations and their percentages of total revenue for the periods indicated. (dollars in millions):

	Three Month June 30, 201	.5	Three Mont June 30, 201	14	
	Amount	%	Amount	%	
Net sales	\$217.3	100.0	\$219.5	100.0	
Cost of goods sold	176.3	81.1	166.9	76.0	
Gross profit	41.0	18.9	52.6	24.0	
Operating expenses:					
Selling, general and administrative	18.7	8.6	19.7	9.0	
Research & development	1.0	0.5	1.1	0.5	
Income from operations	21.3	9.8	31.8	14.5	
Interest expense, net	1.4	0.6	1.1	0.5	
Foreign exchange losses (gains), net	0.2	0.1	(1.0	) (0.5	)
Provision for income taxes	6.1	2.8	11.1	5.1	
Net income	\$13.6	6.3	\$20.6	9.4	
	Q1 3.5 1	r 1 1	C' M 41	T2 4 4	
	Six Months	Ended	Six Months	Enaea	
	Six Months June 30, 201		June 30, 201		
Net sales	June 30, 201	.5	June 30, 201	14	
Net sales Cost of goods sold	June 30, 201 Amount	5 %	June 30, 201 Amount	14 %	
	June 30, 201 Amount \$418.9	5 % 100.0	June 30, 201 Amount \$435.9	14 % 100.0	
Cost of goods sold Gross profit	June 30, 201 Amount \$418.9 337.4	5 % 100.0 80.5	June 30, 201 Amount \$435.9 341.4	14 % 100.0 78.3	
Cost of goods sold	June 30, 201 Amount \$418.9 337.4	5 % 100.0 80.5	June 30, 201 Amount \$435.9 341.4	14 % 100.0 78.3	
Cost of goods sold Gross profit Operating expenses:	June 30, 201 Amount \$418.9 337.4 81.5	5 % 100.0 80.5 19.5	June 30, 201 Amount \$435.9 341.4 94.5	78.3 21.7	
Cost of goods sold Gross profit Operating expenses: Selling, general and administrative	June 30, 201 Amount \$418.9 337.4 81.5	5 % 100.0 80.5 19.5 8.7	June 30, 201 Amount \$435.9 341.4 94.5	14 % 100.0 78.3 21.7 8.9	
Cost of goods sold Gross profit Operating expenses: Selling, general and administrative Research & development	June 30, 201 Amount \$418.9 337.4 81.5 36.6 2.3	5 % 100.0 80.5 19.5 8.7 0.5	June 30, 201 Amount \$435.9 341.4 94.5 38.6 2.1	14 % 100.0 78.3 21.7 8.9 0.5	
Cost of goods sold Gross profit Operating expenses: Selling, general and administrative Research & development Income from operations	June 30, 201 Amount \$418.9 337.4 81.5 36.6 2.3 42.6	5 % 100.0 80.5 19.5 8.7 0.5 10.2	June 30, 201 Amount \$435.9 341.4 94.5 38.6 2.1 53.8	14 % 100.0 78.3 21.7 8.9 0.5 12.3	
Cost of goods sold Gross profit Operating expenses: Selling, general and administrative Research & development Income from operations Interest expense, net	June 30, 201 Amount \$418.9 337.4 81.5 36.6 2.3 42.6 2.6	5 % 100.0 80.5 19.5 8.7 0.5 10.2 0.6	June 30, 201 Amount \$435.9 341.4 94.5 38.6 2.1 53.8	14 % 100.0 78.3 21.7 8.9 0.5 12.3	
Cost of goods sold Gross profit Operating expenses: Selling, general and administrative Research & development Income from operations Interest expense, net Foreign exchange losses (gains), net	June 30, 201 Amount \$418.9 337.4 81.5 36.6 2.3 42.6 2.6 2.4	5 % 100.0 80.5 19.5 8.7 0.5 10.2 0.6 0.6	June 30, 201 Amount \$435.9 341.4 94.5 38.6 2.1 53.8 1.8	14 % 100.0 78.3 21.7 8.9 0.5 12.3 0.4 —	

Three months ended June 30, 2015 compared to the three months ended June 30, 2014 Net Sales

Net sales represent the selling price of the products, net of any customer-related rebates, plus freight and any other items invoiced to customers. Net sales for the three months ended June 30, 2015 were \$217.3 million, a decrease of \$2.2 million, or 1.0%, as compared to \$219.5 million for the same period in 2014. Specialty Phosphates sales were down 3.0% or \$5.9 million with selling prices down 2.0% or \$4.0 million and volume down 1.0% or \$1.9 million. Prices were down primarily in Specialty Ingredients and Food and Technical Grade PPA due to increased competitive pressures from the strength of the US dollar against the euro and Chinese competition in certain markets. The volume decline was mainly in US/Canada Specialty Ingredients due to soft demand in firefighting markets and reduced sales to specialty horticulture markets. GTSP & Other sales were up 17.0% or \$3.7 million with volumes higher by 28.0% or \$6.0 million but prices lower by 11.0% or \$2.3 million.

The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the

prior year to date period volume. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix.

Page 23 of 36

The following table illustrates for the three months ended June 30, 2015 the percentage changes in net sales by reportable segment compared with the same period of the prior year, including the effect of price and volume/mix changes upon revenue:

	Price	Volume/Mix	To	otal
Specialty Phosphates US & Canada	(1.7)	6 (4.0	)% (5.	)%
Specialty Phosphates Mexico	(3.3)	6 10.6	% 7.3	3 %
Total Specialty Phosphates	(2.0)	6 (1.0	)% (3.	.0 )%
GTSP & Other	(11.0 )%	6 28.0	% 17	7.0 %
Total	(2.9)	6 1.9	% (1.	.0 )%

The following table illustrates for the three months ended June 30, 2015 the percentage changes for net sales by Specialty Phosphates product lines compared with the prior year, including the effect of price and volume/mix changes:

	Price		Volume/Mix	Total	
Specialty Ingredients	(2.1	)%	(5.2)%	(7.3	)%
Food & Technical Grade PPA	(3.6	)%	18.7 %	15.1	%
STPP & Detergent Grade PPA	1.5	%	(6.0)	(4.5	)%

### **Gross Profit**

Gross profit represents net sales less cost of goods sold. Gross profit for the three months ended June 30, 2015 was \$41.0 million, a decrease of \$11.6 million, or 22.1%, as compared to \$52.6 million for the same period in 2014. Gross profit percentage decreased to 18.9% for the three months ended June 30, 2015 versus 24.0% for the same period in 2014. Gross profit in 2015 was unfavorably affected primarily by \$6.3 million lower selling prices, \$6.3 million higher manufacturing costs due to higher production and increased spending, and \$1.7 million increased depreciation. These unfavorable effects were partially offset by \$2.1 million favorable exchange rate from our Mexican peso and Canadian dollar based costs. Included in 2014 was \$0.9 million for the accrual of Geismar, La. contingent liabilities. Operating Expenses and Research and Development

Operating expenses consist primarily of selling, general and administrative and research and development expenses. Operating expenses for the three months ended June 30, 2015 were \$19.7 million, a decrease of \$1.1 million, or 5.3%, as compared to \$20.8 million for the same period in 2014. The decrease is primarily due to lower employee related expenses for short term incentive, and favorable exchange rate from our Mexican peso and Canadian dollar based costs.

#### Operating Income

Operating income for the three months ended June 30, 2015 was \$21.3 million, a decrease of \$10.5 million, or 33.0%, as compared to \$31.8 million for the same period in 2014. Operating income as a percentage of net sales decreased to 9.8% versus 14.5% for the same period in 2014, for the reasons noted above.

### Interest Expense, net

Net interest expense, including deferred financing amortization expense, for the three months ended June 30, 2015 was \$1.4 million, an increase of \$0.3 million or 27.3% as compared to \$1.1 million for the same period in 2014. The increase was mainly due to higher average debt levels.

### Foreign Exchange

Foreign exchange for the three months ended June 30, 2015 was a loss of \$0.2 million as compared to a gain of \$1.0 million for the same period in 2014. The U.S. Dollar is the functional currency of our Mexican and Canadian operations. The Company has greater foreign denominated asset balances (largely Mexican Peso and Canadian Dollar), such as VAT receivables and prepaid income taxes in foreign jurisdictions, than offsetting foreign denominated liability balances. As the US dollar strengthened throughout the period versus the Mexican Peso and the

Canadian Dollar, the re-measurement of the net foreign asset denominated balances contributed to a net foreign exchange loss. Consequently, foreign exchange gain or loss is

Page 24 of 36

recorded on re-measurement of non-U.S. dollar denominated monetary assets and liabilities. Such gains and losses fluctuate from period to period as the foreign currencies strengthen or weaken against the U.S. dollar and the amount of non-U.S. dollar denominated assets and liabilities increases or decreases.

**Provision for Income Taxes** 

The effective income tax rate was 31% for the three months ended June 30, 2015 compared to 35% for the same period in 2014. The variance in the effective tax rate is primarily due to an increased proportion of taxable income in lower tax rate jurisdictions.

Net Income

Net income for the three months ended June 30, 2015 was \$13.6 million, a decrease of \$7.0 million as compared to \$20.6 million for the same period in 2014, due to the factors described above.

Six months ended June 30, 2015 compared to the six months ended June 30, 2014 Net Sales

Net sales represent the selling price of the products, net of any customer-related rebates, plus freight and any other items invoiced to customers. Net sales for the six months ended June 30, 2015 were \$418.9 million, a decrease of \$17.0 million, or 3.9%, as compared to \$435.9 million for the same period in 2014. Specialty Phosphates sales were down 3.1% or \$12.0 million with prices lower by 2.1% or \$8.3 million and volumes lower by 1.0% or \$3.7 million. Prices were down mainly in US/Canada Food & Technical Grade PPA and Specialty Ingredients due to increased competitive pressures from the strength of the US dollar against the euro and Chinese competition in certain markets. The volumes decline was mainly in US/Canada Specialty Ingredients due to soft demand in firefighting markets and reduced sales to specialty horticulture markets. The Specialty Ingredients volume decrease was partially offset by an increase in Food & Technical Grade PPA volumes in Mexico. GTSP & Other sales were down 11.7% or \$5.0 million with volumes lower by 15.6% or \$6.6 million but prices higher 3.9% or \$1.6 million.

The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to date period volume. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix. The following table illustrates for the six months ended June 30, 2015 the percentage changes in net sales by reportable segment compared with the same period of the prior year, including the effect of price and volume/mix changes upon revenue:

	Price		Volume/l	Mix	Total	
Specialty Phosphates US & Canada	(2.5	)%	(1.6	)%	(4.1	)%
Specialty Phosphates Mexico	(0.7	)%	1.6	%	0.9	%
Total Specialty Phosphates	(2.1	)%	(1.0	)%	(3.1	)%
GTSP & Other	3.9	%	(15.6	)%	(11.7	)%
Total	(1.5	)%	(2.4	)%	(3.9	)%

The following table illustrates for the six months ended June 30, 2015 the percentage changes for net sales by Specialty Phosphates product lines compared with the prior year, including the effect of price and volume/mix changes:

	Price	Volume/Mix	Total
Specialty Ingredients	(2.3)	% (3.7	% (6.0 )%
Food & Technical Grade PPA	(2.7)	% 10.8	% 8.1 %
STPP & Detergent Grade PPA	0.3	% (2.7	% (2.4 )%

# Gross Profit

Gross profit represents net sales less cost of goods sold. Gross profit for the six months ended June 30, 2015 was \$81.5 million, a decrease of \$13.0 million, or 13.8%, as compared to \$94.5 million for the same period in 2014. Gross

profit percentage decreased to 19.5% for the six months ended June 30, 2015 versus 21.7% for the same period in 2014.

Gross profit in 2015 was unfavorably affected by \$9.7 million higher manufacturing costs due to higher production and increased spending, \$6.6 million lower selling prices, \$3.0 million higher depreciation, \$2.2 million in planned maintenance

Page 25 of 36

outage expense at our Coatzacoalcos, Mexico manufacturing facility, \$0.9 million for a GTSP lower of cost or market reserve and \$0.6 million unfavorable sales volume effects. These favorable effects were partially offset by \$5.3 million lower raw material costs and \$3.8 million favorable exchange rate from Mexican peso and Canadian dollar based costs. Included in 2014 was \$0.9 million for the accrual of Geismar, La. contingent liabilities.

Operating Expenses and Research and Development

Operating expenses consist primarily of selling, general and administrative and research and development expenses. Operating expenses for the six months ended June 30, 2015 were \$38.9 million, a decrease of \$1.8 million, or 4.4%, as compared to \$40.7 million for the same period in 2014. The decrease is primarily due to \$1.5 million decreased employee related expense for short term incentive accruals and stock compensation and \$0.6 million favorable exchange rate from Mexican peso and Canadian dollar based costs.

# Operating Income

Operating income for the six months ended June 30, 2015 was \$42.6 million, a decrease of \$11.2 million, or 20.8%, as compared to \$53.8 million for the same period in 2014. Operating income as a percentage of net sales decreased to 10.2% versus 12.3% for the same period in 2014, for the reasons noted above.

# Interest Expense, net

Net interest expense, including deferred financing amortization expense, for the six months ended June 30, 2015 was \$2.6 million, an increase of \$0.8 million, or 44.4% as compared to \$1.8 million for the same period in 2014. The increase was mainly due to higher average debt levels and a \$0.5 million interest benefit in 2014 for income tax audits in the US.

# Foreign Exchange

Foreign exchange for the six months ended June 30, 2015 was a loss of \$2.4 million as compared zero for the same period in 2014. The U.S. Dollar is the functional currency of our Mexican and Canadian operations. The Company has greater foreign denominated asset balances (largely Mexican Peso and Canadian Dollar), such as VAT receivables and prepaid income taxes in foreign jurisdictions, than offsetting foreign denominated liability balances. As the US dollar strengthened throughout the period versus the Mexican Peso and the Canadian Dollar, the re-measurement of the net foreign asset denominated balances contributed to a net foreign exchange loss. Consequently, foreign exchange gain or loss is recorded on re-measurement of non-U.S. dollar denominated monetary assets and liabilities. Such gains and losses fluctuate from period to period as the foreign currencies strengthen or weaken against the U.S. dollar and the amount of non-U.S. dollar denominated assets and liabilities increases or decreases.

### Provision for Income Taxes

The effective income tax rate was 32% for the six months ended June 30, 2015 compared to 33% for the same period in 2014. The variance in the effective tax rate is primarily due to uncertain income tax position benefits which decreased the effective tax rate by 1% in the prior year and R&D and state research and development credits which decreased the prior year effective tax rate by 1%, both of which were more than offset by the effects of an increased proportion of taxable income in lower tax rate jurisdictions in the current year.

# Net Income

Net income for the six months ended June 30, 2015 was \$25.5 million, a decrease of \$9.3 million as compared to \$34.8 million for the same period in 2014, due to the factors described above.

Page 26 of 36

# **Segment Reporting**

The Company reports its core Specialty Phosphates business separately from GTSP & Other. Specialty Phosphates consists of the products lines Specialty Ingredients, Food & Technical Grade PPA and STPP & Detergent Grade PPA. Innophos Nutrition is included in the Specialty Phosphates US & Canada segment and in the Specialty Ingredients product line. GTSP & Other includes fertilizer co-product GTSP and other non-Specialty Phosphate products. The primary performance indicators for the chief operating decision maker are sales and operating income. The following table sets forth the historical results of these indicators by segment:

	Three Months Ended					
	June 30, June 30,		June 30,	Net Sales %		
	2015		2014		Change	
Segment Net Sales						
Specialty Phosphates US & Canada	\$148,376		\$157,267		(5.7	)%
Specialty Phosphates Mexico	43,886		40,885		7.3	%
Total Specialty Phosphates	192,262		198,152		(3.0	)%
GTSP & Other	25,032		21,390		17.0	%
Total	\$217,294		\$219,542		(1.0	)%
Segment Operating Income						
Specialty Phosphates US & Canada	\$13,470		\$21,334			
Specialty Phosphates Mexico	7,362	10,320				
Total Specialty Phosphates	20,832	31,654				
GTSP & Other	433		155			
Total	\$21,265		\$31,809			
Segment Operating Income % of net sales						
Specialty Phosphates US & Canada	9.1	%	13.6	%		
Specialty Phosphates Mexico	16.8	%	25.2	%		
Total Specialty Phosphates	10.8	%	16.0	%		
GTSP & Other	1.7	%	0.7	%		
Total	9.8	%	14.5	%		
Depreciation and amortization expense						
Specialty Phosphates US & Canada	\$6,786		\$6,291			
Specialty Phosphates Mexico	3,196	2,277				
Total Specialty Phosphates	\$9,982		\$8,568			
GTSP & Other	780		357			
Total	\$10,762		\$8,925			

Page 27 of 36

	Six Months Ended					
	June 30,		June 30,		Net Sales %	
	2015		2014		Change	
Segment Net Sales						
Specialty Phosphates US & Canada	\$295,500		\$308,277		(4.1	)%
Specialty Phosphates Mexico	86,106		85,374		0.9	%
Total Specialty Phosphates	381,606		393,651		(3.1	)%
GTSP & Other	37,297		42,232		(11.7	)%
Total	\$418,903		\$435,883		(3.9	)%
Segment Operating Income						
Specialty Phosphates US & Canada	\$29,657		\$41,547			
Specialty Phosphates Mexico	14,281		16,181			
Total Specialty Phosphates	43,938		57,728			
GTSP & Other	(1,312	)	(3,975	)		
Total	\$42,626		\$53,753			
Segment Operating Income % of net sales						
Specialty Phosphates US & Canada	10.0	%	13.5	%		
Specialty Phosphates Mexico	16.6	%	19.0	%		
Total Specialty Phosphates	11.5	%	14.7	%		
GTSP & Other	(3.5	)%	(9.4	)%		
Total	10.2	%	12.3	%		
Depreciation and amortization expense						
Specialty Phosphates US & Canada	\$13,725		\$11,609			
Specialty Phosphates Mexico	5,294		5,046			
Total Specialty Phosphates	\$19,019		\$16,655			
GTSP & Other	1,614		744			
Total	\$20,633		\$17,399			

Three months ended June 30, 2015 compared to the three months ended June 30, 2014

Segment Net Sales:

Specialty Phosphates US & Canada net sales decreased 5.7% for the three months ended June 30, 2015 when compared with the same period in 2014. Average selling prices decreased by 1.7% primarily in Specialty Ingredients and Food & Technical Grade PPA while volumes decreased 4.0% primarily in Specialty Ingredients.

Specialty Phosphates Mexico net sales increased 7.3% for the three months ended June 30, 2015 when compared with the same period in 2014. Volumes increased 10.6% primarily in Food & Technical Grade PPA while selling prices decreased 3.3% primarily in Specialty Ingredients.

GTSP & Other net sales increased 17.0% for the three months ended June 30, 2015 when compared with the same period in 2014. Volumes increased 28.0% while selling prices decreased 11.0%.

Segment Operating Income Percentage of Net Sales:

The 450 basis point decrease in Specialty Phosphates US & Canada operating income margins for the three months ended June 30, 2015 compared with the same period in 2014 is due to higher raw material costs, mainly PPA and Merchant Green Acid, which decreased margins by 180 basis points, lower selling prices which decreased margins by 150 basis points, higher manufacturing expenses which decreased margins by 130 basis points and decreased sales volume/mix which decreased margins by 60 basis points. This was partially offset by lower operating expenses which increased margins by 70 basis points.

The 840 basis point decrease in Specialty Phosphates Mexico operating income margins for the three months ended June 30, 2015 compared with the same period in 2014 is due to higher raw material costs, mainly sulfur, which

decreased margins

Page 28 of 36

by 490 basis points, higher manufacturing and operating expenses which decreased margins by 270 basis points, lower selling prices which decreased margins by 250 basis points and higher depreciation which decreased margins by 220 basis points. This was partially offset by favorable exchange rate effects which increased margins by 340 basis points and increased sales volume/mix which increased margins by 50 basis points.

The 100 basis point increase in GTSP & Other operating income margins for the three months ended June 30, 2015 compared with the same period in 2014 is due to lower raw material cost which increased margins by 2,160 basis points, favorable exchange rate effects which increased margins by 220 basis points, favorable volume effects which increased margins by 180 basis points and lower operating expenses which increased margins by 70 basis points. This was mostly offset by higher manufacturing costs which decreased margins by 1,530 basis points, lower selling prices which decreased margins by 1,220 basis points and higher depreciation which decreased margins by 200 basis points. Included in 2014 was the accrual of Geismar La. contingent liabilities which increase margins by 420 basis points in 2015.

Six months ended June 30, 2015 compared to the six months ended June 30, 2014 Segment Net Sales:

Specialty Phosphates US & Canada net sales decreased 4.1% for the six months ended June 30, 2015 when compared with the same period in 2014. Average selling prices decreased by 2.5%, mainly in Specialty Ingredients and Food & Technical Grade PPA, and volumes decreased 1.6% with decreases in Specialty Ingredients partially offset by increased Food & Technical PPA.

Specialty Phosphates Mexico net sales increased 0.9% for the six months ended June 30, 2015 when compared with the same period in 2014. Volumes increased 1.6% mainly in Food & Technical Grade PPA while selling prices decreased 0.7% mainly in Specialty Ingredients.

GTSP & Other net sales decreased 11.7% for the six months ended June 30, 2015 when compared with the same period in 2014. Volumes decreased 15.6% while selling prices increased 3.9%.

Segment Operating Income Percentage of Net Sales:

The 350 basis point decrease in Specialty Phosphates US & Canada for the six months ended June 30, 2015 compared with the same period in 2014 is due lower average selling prices which decreased margins by 220 basis points, higher manufacturing cost, including exchange which decreased margins by 170 basis points, higher depreciation which decreased margins by 70 basis points and lower sales volume/mix which reduced margins by 30 basis points. This was partially offset by decreased raw material costs which increased margins 80 basis points and lower operating expenses which increased margins by 60 basis points.

The 240 point decrease in Specialty Phosphates Mexico for the six months ended June 30, 2015 compared with the same period in 2014 is due to by a planned maintenance outage expenses which decreased margins by 190 basis points, higher manufacturing and operating cost which decreased margins by 200 basis points, higher raw material costs which decreased margins by 100 basis points, lower average selling prices which decreased margins by 60 basis points and higher depreciation which decreased margins by 30 basis points. This was partially offset by favorable exchange rate effects which increased margins by 340 basis points.

The 590 basis point increase in GTSP & Other for the six months ended June 30, 2015 compared with the same period in 2014 is due to lower raw material cost which increased margins by 910 basis points, higher selling prices which increased margins 410 basis points, favorable exchange rate effect which increased margins by 230 basis points and lower operating costs which increased margins by 10 basis points. This was partially offset by higher manufacturing costs which lowered margins 600 basis points, higher depreciation which decreased margins by 210 basis points, a lower of cost or market reserve which decreased margins by 210 basis points, planned maintenance outage expenses which decreased margins by 130 basis points and lower sales volume/mix which decreased margins by 30 basis points. Included in 2014 was the accrual of Geismar La. contingent liabilities which increase margins by 210 basis points in 2015.

# Liquidity and Capital Resources

The following table sets forth a summary of the Company's cash flows for the periods indicated.

(Dollars in millions)	Six months ended		
	June 30,	June 30,	
	2015	2014	
Operating Activities	\$55.3	\$68.0	
Investing Activities	(14.1	) (14.7	
Financing Activities	2.6	(47.6)	
Effect of foreign exchange rate changes			

Six months ended June 30, 2015 compared to six months ended June 30, 2014

Net cash provided by operating activities was \$55.3 million for the six months ended June 30, 2015 as compared to \$68.0 million for 2014, a decrease of \$12.8 million. The decrease in operating activities cash resulted from unfavorable changes of \$4.7 in working capital, \$9.3 million in net income, as described earlier, and \$1.9 million in other long term assets and liabilities partially offset by favorable changes of \$3.1 million in non-cash adjustments to income.

The unfavorable change in working capital is derived from it being a source of cash of \$6.9 million in 2015 compared to a source in 2014 of \$11.6 million, a decrease in cash of \$4.7 million. The unfavorable change in working capital was due to unfavorable changes in inventory of \$7.6 million, other current liabilities of \$4.1 million and accounts payable of \$3.2 million partially offset by favorable changes in accounts receivable of \$8.4 million and other current assets of \$1.8 million. Accounts receivable as a percent of quarterly sales, when adjusted for GTSP open accounts receivable of \$0.9 million, \$0.8 million, \$0.9 million, \$2.2 million and \$11.0 million as of June 30, 2015, March 31, 2015, December 31, 2014, September 30, 2014, and June 30, 2014 respectively, was consistent with the last four quarters' average.

Net cash used for investing activities was \$14.1 million for the six months ended June 30, 2015, compared to \$14.7 million for 2014, a decrease in spending of \$0.6 million.

Approximately 70% of the year-to-date June 2015 capital spending was for maintenance and the remaining 30% was for strategic growth initiatives. The majority of the strategic growth investments were focused on improving the capacity and capability of Coatzacoalcos. Our expectation for 2015 capital expenditures remains in the \$30-35 million range with the maintenance portion of these capital expenditures expected to be within the typical \$20-\$25 million range.

Innophos currently estimates that full exploration costs to a proven reserves standard for its Baja California mining concession could require expenditures of \$10 to \$15 million over the next three to four years. This estimate includes mineral rights payments, taxes, mineral resource measurement, beneficiation process design and completion of feasibility studies. Full expenditures would only occur if interim milestone goals are successfully attained. Combined 2010 through 2014 expenditures on the exploration of the Baja California Sur concession deposits were approximately \$5.0 million. Spending in 2015 will likely be lower. Innophos intends to seek one or more partners for these efforts, but anticipates no difficulties in completing the exploration phase without a partnership.

Net cash from financing activities for the six months ended June 30, 2015, was a source of \$2.6 million, compared to a use of \$47.6 million in 2014, an increase in cash of \$50.2 million. This was largely due to \$110.0 million increased loan borrowings and \$22.0 million decreased loan repayments partially offset by \$79.9 million increased stock repurchases and \$2.5 million higher dividend payments. The loan borrowings were partially used to fund the stock repurchases.

Innophos and its subsidiaries and affiliates may from time to time seek to acquire or otherwise retire outstanding debt through privately negotiated transactions, exchanges or otherwise. Debt repurchases or exchanges, if any, will depend on prevailing market conditions, Company liquidity requirements, restrictive financial covenants and other factors applicable at the time. The amounts involved may be material.

In December 2014 the company's Board of Directors authorized a new share repurchase program for the company's common stock for a total consideration of \$125 million. The program began on January 1, 2015 and will remain active for a maximum duration of twelve months. Under the program shares will be repurchased at management's discretion, either through open market transactions, block purchases, private transactions or other means and will be funded through existing liquidity and cash from operations. The exact number and timing of the share repurchases will depend on market conditions and other

Page 30 of 36

factors. Under the stock repurchase program, during the six months ended June 30, 2015, the Company repurchased 1,555,726 shares of its common stock on the open market at an average price of \$55.18 per share or \$85.8 million. The Company has \$39 million of share repurchases left to fulfill the \$125 million program for 2015 which will likely be funded with further borrowings on the Credit Facility. As a result of lower than expected earnings for 2015 combined with the increased borrowings to fund the share repurchase program, the Company's Senior Leverage Ratio has increased from 0.98 as of December 31, 2014 to 1.89 as of June 30, 2015. In order to make restricted payments such as share repurchases or dividends, the Company must pass an incurrence test of (a) the Total Leverage Ratio and Senior Leverage Ratio shall be 0.50 less than the applicable covenant level and (b) accessible borrowing availability of at least \$25.0 million. The applicable Senior Leverage Ratio for the incurrence test is 2.00 to 1.00 which the Company is in compliance with at June 30, 2015. The Company is currently negotiating with the lenders to amend the Credit Agreement to adjust or remove the Senior Leverage Ratio. In the event of unsuccessful negotiations with the lenders, the Company may have to take other courses of action, including but not limited to decreasing the rate of share repurchases. The Company expects to remain in compliance with all debt covenants for the next twelve months. On June 30, 2015, the Company had cash and cash equivalents outside the United States of \$67.4 million, or 84% of the Company's balance. Furthermore, the foreign cash amounts are not restricted by law to be used in other countries. Our current operating plan does not include repatriation of any of the cash and cash equivalents held outside the United States to fund the United States operations. However, in the event we do repatriate cash and cash equivalents held outside of the United States, we may be required to accrue and pay United States income taxes to repatriate these

We believe that on-hand cash combined with cash generated from operations, including our Mexican and Canadian operations will be sufficient to meet our obligations such as debt service, tax payments, capital expenditures, dividend payments and working capital requirements for at least the next twelve months. We expect to fund all of these obligations through our existing cash and our future operating cash flows. However, future operating performance for the Company is subject to prevailing economic and competitive conditions and various other factors that are uncertain. If the cash flows and other capital resources available to the Company, such as its revolving loan facility, are insufficient to fund our debt and other liquidity needs, the Company may have to take alternative actions that differ from current operating plans.

# Critical Accounting Estimates and Policies Goodwill

As of January 1, 2015, our Kelatron, AMT, Triarco and CMI reporting units for goodwill purposes have been combined into one reporting unit, Innophos Nutrition. Our reporting units for goodwill purposes are Specialty Phosphates United States, Specialty Phosphates Canada, Specialty Phosphates Mexico, Innophos Nutrition and GTSP & Other. As of December 31, 2014, the fair values of our reporting units were substantially greater than their carrying values.

Other than the above, there have been no material changes from the critical accounting estimates previously disclosed in our 2014 Annual Report on Form 10-K.

Page 31 of 36

# ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to certain market risks as part of our ongoing business operations. Primary exposures include changes in interest rates, as borrowings under our Loan Agreement will bear interest at floating rates based on LIBOR plus an applicable borrowing margin. We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with our credit status. For fixed-rate debt, interest rate changes do not affect earnings or cash flows. Conversely, for floating-rate debt, interest rate changes generally affect our earnings and cash flows, assuming other factors are held constant.

At June 30, 2015, we had \$90 million principal amount of variable-rate debt remaining on a term loan and a \$225.0 million revolving credit facility, of which \$154.0 million was outstanding, both of which approximate fair value (determined using level 2 inputs within the fair value hierarchy). Total remaining availability was \$70.1 million, taking into account \$0.9 million in face amount of letters of credit issued under the sub-facility. Simultaneously with initiating the new senior facility, Innophos entered into an interest rate swap, swapping the LIBOR exposure on \$100.0 million of floating rate debt with a fixed rate of 0.9475% plus the applicable margin on the debt expiring in December 2017. This interest rate swap has been designated as a cash flow hedge with the changes in value recorded through other comprehensive income. The fair value of this interest rate swap is an asset of approximately \$0.1 million (determined using level 2 inputs within the fair value hierarchy) as of June 30, 2015.

Changes in economic conditions could result in higher interest rates, thereby increasing our interest expense on our revolving line of credit. Changes in economic conditions may also result in lower operating income, reducing our funds available for capital investment, operations or other purposes. In addition, a substantial portion of our operating cash flow and available borrowing capacity on our credit facility has been used to repurchase shares, pay dividends, fund capital expenditures, fund working capital needs and service debt, which may affect our ability to make future acquisitions. We may from time to time use interest rate protection agreements to minimize our exposure to interest rate fluctuation. Regardless of hedges, we may experience economic loss and a negative impact on earnings or net assets as a result of interest rate fluctuations. Based on \$144.0 million outstanding borrowings as floating rate debt (amount not covered by the swap), an immediate increase of one percentage point would cause an increase to interest expense of approximately \$1.4 million per year.

We currently do not have any, but from time to time, we may enter into longer term natural gas supply contracts in an effort to eliminate some of the volatility in our energy costs.

We do not currently hedge our currency rate risks.

We believe that our concentration of credit risk related to trade accounts receivable is limited since these receivables are spread among a number of customers and are geographically dispersed. No customer accounted for more than 10% of our sales in the last 3 years.

Foreign Currency Exchange Rates

The U.S. Dollar is the functional currency of the Canadian and Mexican operations. Accordingly, these operations' monetary assets and liabilities are translated at current exchange rates, non-monetary assets and liabilities are translated at historical exchange rates, and revenue and expenses are translated at average exchange rates and at historical exchange rates for the related revenue and expenses of non-monetary assets and liabilities. All transaction gains and losses are included in net income.

Our principal source of exchange rate exposure in our foreign operations consists of expenses, such as labor expenses, which are denominated in the foreign currency of the country in which we operate. A decline in the value of the U.S. Dollar relative to the local currency would generally cause our operational expenses (particularly labor costs) to increase (conversely, a decline in the value of the foreign currency relative to the U.S. Dollar would cause these expenses to decrease). We believe that normal exchange rate fluctuations consistent with recent historical trends would have a modest impact on our expenses, and would not materially affect our financial condition or results of operations. Nearly all of our sales are denominated in U.S. Dollars and our exchange rate exposure in terms of sales revenues is minimal. However, the strength or weakness of the USD versus other currencies can affect our competitiveness in the U.S. market.

Inflation and changing prices

Our costs and expenses will be subject to inflation and price fluctuations. Significant price fluctuations in raw materials, freight, and energy costs, if not compensated for by cost savings from production efficiencies or price increases passed on to customers could have a material effect on our financial condition and results of operations.

Page 32 of 36

# Off-Balance Sheet Arrangements

We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as "structured finance or special purpose entities", which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

### ITEM 4. CONTROLS AND PROCEDURES

### Disclosure Control and Procedures

The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) that are designed to provide reasonable assurance that information required to be reported in the Company's consolidated financial statements and filings is recorded, processed, summarized and reported within the periods specified in the rules and forms of the Securities and Exchange Commission, or SEC, and that such information is accumulated and communicated to the Company's management, including its Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.

As of June 30, 2015 the Company completed an evaluation under the supervision and with the participation of the Company's management, including the Company's Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based upon that evaluation, the Principal Executive Officer and Principal Financial Officer concluded that the Company's disclosure controls and procedures are effective at the reasonable assurance level.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during or with respect to the second quarter of 2015 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Page 33 of 36

### **PART II**

# ITEM 1. LEGAL PROCEEDINGS

Note 12 of Notes to Consolidated Condensed Financial Statements in "Item 1. Financial Statements" contained in this Quarterly Report on Form 10-Q is incorporated herein by reference.

### ITEM 1A. RISK FACTORS

There have been no material changes from the risk factors previously disclosed in our 2014 Annual Report on Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

# ITEM 4. MINE SAFETY DISCLOSURES

None.

### ITEM 5. OTHER INFORMATION

None.

### ITEM 6. EXHIBITS

a) Exhibits. The following exhibits are filed or furnished as part of this report:

Exhibit No. Description

Certification of Principal Executive Officer dated July 29, 2015 pursuant to Section 302 of

the Sarbanes-Oxley Act of 2002

31.2 Certification of Principal Financial Officer dated July 29, 2015 pursuant to Section 302 of

the Sarbanes-Oxley Act of 2002

32.1\* Certification of Principal Executive Officer dated July 29, 2015 pursuant to Section 906 of

the Sarbanes-Oxley Act of 2002

32.2\* Certification of Principal Financial Officer dated July 29, 2015 pursuant to Section 906 of

the Sarbanes-Oxley Act of 2002

Not to be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to

\* the liability of that section, nor deemed to be incorporated by reference into any filing under that Act or the Securities Act of 1933.

Page 34 of 36

# **Table of Contents**

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INNOPHOS HOLDINGS, INC.

/s/ Randolph Gress

By: Randolph Gress

Its: Chief Executive Officer and Director

(Principal Executive Officer)

Dated: July 29, 2015

INNOPHOS HOLDINGS, INC.

/s/ Robert Harrer

By: Robert Harrer

Its: Vice President and Chief Financial Officer

(Principal Financial Officer)

Dated: July 29, 2015

Page 35 of 36

# **Table of Contents**

# EXHIBIT INDEX Exhibit No. Description Certification of Principal Executive Officer dated July 29, 2015 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Certification of Principal Financial Officer dated July 29, 2015 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Certification of Principal Executive Officer dated July 29, 2015 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Certification of Principal Financial Officer dated July 29, 2015 pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

Page 36 of 36

32.2